Our Founders

Thomas A. Harlan, CEO of Emergent Technologies, Inc. and Dr. William Hildebrand, Chief Scientist at Pure MHC and Research Professor in the OU Department of Microbiology and Immunology, co-founded Pure MHC to leverage the sHLA platform technology of Pure Protein in the discovery of HLA Class I and Class II peptide targets for use immunotherapies to cancer, infectious disease, and autoimmune diseases.

Tommy Harlan and William Hildebrand, PhD

Our Team

The Pure MHC team has considerable expertise in biochemistry, immunology, pharmaceutical biotechnology, microbiology and organic chemistry and bench proficiency in mass spectrometry, proteomics, peptidomics, informatics, tissue culture, epitope screening & validation, peptide binding, HLA extraction, as well as the transfection, production, and purification of the company’s proprietary soluble HLA proteins.